184 related articles for article (PubMed ID: 36201324)
1. LP07 and LLC preclinical models of lung cancer induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting.
Belcher DJ; Guitart M; Hain B; Kim HG; Waning D; Barreiro E; Nader GA
J Appl Physiol (1985); 2022 Dec; 133(6):1260-1272. PubMed ID: 36201324
[TBL] [Abstract][Full Text] [Related]
2. Metastatic or xenograft colorectal cancer models induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting in a tumor-type-dependent manner.
Kim HG; Huot JR; Pin F; Belcher DJ; Bonetto A; Nader GA
J Appl Physiol (1985); 2022 Dec; 133(6):1273-1283. PubMed ID: 36201323
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
4. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
5. Diet-induced obesity does not exacerbate cachexia in male mice bearing Lewis-lung carcinoma tumors.
Beaudry AG; Law ML; Gilley-Connor KR; Buley H; Dungan CM; Nascimento CMC; Vichaya EG; Wiggs MP
Am J Physiol Regul Integr Comp Physiol; 2024 Mar; 326(3):R254-R265. PubMed ID: 38252513
[TBL] [Abstract][Full Text] [Related]
6. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
7. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
8. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.
Zhang G; Jin B; Li YP
EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300.
Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP
Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic analysis of the development of skeletal muscle atrophy in cancer-cachexia in tumor-bearing mice.
Blackwell TA; Cervenka I; Khatri B; Brown JL; Rosa-Caldwell ME; Lee DE; Perry RA; Brown LA; Haynie WS; Wiggs MP; Bottje WG; Washington TA; Kong BC; Ruas JL; Greene NP
Physiol Genomics; 2018 Dec; 50(12):1071-1082. PubMed ID: 30289747
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia.
Bohnert KR; Gallot YS; Sato S; Xiong G; Hindi SM; Kumar A
FASEB J; 2016 Sep; 30(9):3053-68. PubMed ID: 27206451
[TBL] [Abstract][Full Text] [Related]
14. β‑carotene attenuates muscle wasting in cancer cachexia by regulating myogenesis and muscle atrophy.
Kim Y; Oh Y; Kim YS; Shin JH; Lee YS; Kim Y
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37975253
[TBL] [Abstract][Full Text] [Related]
15. Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia.
Kim HG; Huot JR; Pin F; Guo B; Bonetto A; Nader GA
FASEB J; 2021 Feb; 35(2):e21335. PubMed ID: 33527503
[TBL] [Abstract][Full Text] [Related]
16. PGC-1α overexpression is not sufficient to mitigate cancer cachexia in either male or female mice.
Morena da Silva F; Rosa-Caldwell ME; Schrems ER; Martinez L; Amos MG; Lim S; Cabrera AR; Brown JL; Washington TA; Greene NP
Appl Physiol Nutr Metab; 2022 Sep; 47(9):933-948. PubMed ID: 35700525
[TBL] [Abstract][Full Text] [Related]
17. Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia.
Cardaci TD; VanderVeen BN; Bullard BM; McDonald SJ; Unger CA; Enos RT; Fan D; Velázquez KT; Frizzell N; Spangenburg EE; Murphy EA
J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):124-137. PubMed ID: 38062911
[TBL] [Abstract][Full Text] [Related]
18. Comparative plasma proteomics in muscle atrophy during cancer-cachexia and disuse: The search for atrokines.
Lim S; Dunlap KR; Rosa-Caldwell ME; Haynie WS; Jansen LT; Washington TA; Greene NP
Physiol Rep; 2020 Oct; 8(19):e14608. PubMed ID: 33063952
[TBL] [Abstract][Full Text] [Related]
19. REDD1 deletion attenuates cancer cachexia in mice.
Hain BA; Xu H; VanCleave AM; Gordon BS; Kimball SR; Waning DL
J Appl Physiol (1985); 2021 Dec; 131(6):1718-1730. PubMed ID: 34672766
[TBL] [Abstract][Full Text] [Related]
20. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1.
Chen C; Ju R; Zhu L; Li J; Chen W; Zhang DC; Ye CY; Guo L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):423-433. PubMed ID: 28124088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]